Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T18:56:56.594Z.
Calculation as of: 2026-10-06T18:56:56.594Z.
Quote observation: 2026-10-06T18:53:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8e2f3ec51e074b036058196f7f903a3cac1545bb57f25a27b7ce4fd0c255fbf9
PEG RATIO
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Galectin Therapeutics Inc. (GALT) | $243.01M | N/A | N/A | N/A | N/A |
| Lifecore Biomedical, Inc. (LFCR)vs › | $242.31M | N/A | 2.31 | 2.31 | 2.31 |
| Q32 Bio Inc. (QTTB)vs › | $242.58M | N/A | N/A | N/A | N/A |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $238.81M | N/A | N/A | N/A | N/A |
| Century Therapeutics, Inc. (IPSC)vs › | $245.36M | N/A | N/A | N/A | N/A |
| Quantum-Si incorporated (QSI)vs › | $246.29M | N/A | N/A | N/A | N/A |
| High Tide Inc. (HITI)vs › | $237.69M | N/A | N/A | N/A | N/A |
| Sol-Gel Technologies Ltd. (SLGL)vs › | $246.81M | N/A | N/A | N/A | N/A |
| Invivyd, Inc. (IVVD)vs › | $237.36M | N/A | N/A | N/A | N/A |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $236.58M | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute